Clinical Application of Real-World Evidence for Stroke Prevention in Atrial Fibrillation and the Treatment of Venous Thromboembolism (CARE-AF/VTE Program)

Atrial Fibrillation Course Information

Description

Atrial fibrillation (AF) is a leading cause of stroke, yet many patients eligible for oral anticoagulant therapy are not receiving guideline-directed care. Real-world evidence highlights significant gaps in the optimal use of direct oral anticoagulants (DOACs), with many patients either under-treated or incorrectly dosed. These gaps contribute to higher rates of stroke and other adverse outcomes in AF patients, particularly in high-risk populations. This program will focus on enhancing clinicians' understanding of the latest evidence-based practices for anticoagulation therapy in AF, addressing the underuse of DOACs and common dosing errors to improve patient care and outcomes.

Participants will explore clinical decision-making strategies and practical applications of real-world data to align treatment with current guidelines.

Lessons will be released weekly and then permanently available to registered attendees.

Faculty: Gregory Y. H. Lip, MD, FRCP (London Edinburgh Glasgow), DFM, AFHEA, FACC, FESC, FEHRA, iFAPHRS

Session 1: Direct Oral Anticoagulant Use in Atrial Fibrillation
January 13, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Evaluate the key findings from controlled trials supporting the efficacy and safety of Direct Oral Anticoagulants (DOACs) compared to Vitamin K Antagonists (VKAs) for stroke prevention in atrial fibrillation
Analyze how the efficacy and safety of DOACs in real-world settings compares to their performance in randomized controlled trials
Identify differences between individual DOACs in real-world practice and their clinical application in practice

Session 2: Direct Oral Anticoagulant Use in Special Populations with Atrial Fibrillation
January 20, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Explain the types of valvular heart disease (VHD) in which Direct Oral Anticoagulants (DOACs) can be safely utilized
Apply knowledge of kidney disease stages to determine the appropriate utility and necessary dose adjustments of DOACs are necessary
Develop dosing strategies for patients at extremes of body weight, incorporating guidelines for DOAC choice and dosing based on patient-specific factors

Session 3: Anticoagulation Stewardship of Direct Oral Anticoagulant Therapy in Atrial Fibrillation
January 27, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Analyze the metabolic pathways leading to key drug interactions that are clinically relevant with direct oral anticoagulant (DOAC) therapy
Evaluate the impact of patient adherence on the efficacy and safety of DOAC therapy using real-world data across the world
Define the role of anticoagulation stewardship in overcoming challenges and ensuring best practice in anticoagulant therapy

Session 4: Atrial Fibrillation – Q&A with Experts
February 7, 2025 | 3:00pm - 4:00pm CEST

Faculty: Gregory Y. H. Lip, MD; Walter Ageno, MD; Edelgard Lindhoff-Last, MD; Karina Meijer, MD, PhD; G. Andrei Dan, MD; and Mark Crowther, MD, MSc (moderator)

Still have questions on stroke prevention in atrial fibrillation? Join our panel of international experts LIVE on Friday, February 7, 2025 from 3:00pm-4:00pm CEST (Central European Standard Time). Submit your questions ahead of time through the learning module website.

Atrial Fibrillation Course Free Registration

Please log into your account to register for this course.

Accreditation CE Hours

This 4-week program is accredited for up to 2.5 hours of continuing education credits for physicians, nurses, and pharmacists.

Venous Thromboembolism Course Remember to register for the Venous Thromboembolism part of the course!

This program will examine gaps in clinician knowledge and anticoagulation stewardship, focusing on real-world evidence and practical strategies to improve guideline-based treatment of VTE, especially in managing complex, high-risk, and underrepresented patient populations. Participants will explore clinical decision-making strategies and practical applications of real-world data to align treatment with current guidelines.